Jupiter Neurosciences (JUNS) Launches Nugevia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
June 9, 2025 7:00 AM EDTFirst consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (Jupiter or the Company), a clinical-stage pharmaceutical company developing JOTROL, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia, its consumer longevity product line. The launch represents a pivotal milestone in Jupiters strategy to generate near-term revenue while maintaining momentum in its clinical pipeline.
Nugevias debut comes as global demand accelerates... More
